Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Po Zhang

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarizationJinyang Hu, Feng Dong, You He, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 12, 2009
Targeted disruption of the voltage-dependent calcium channel alpha2/delta-1-subunitGeraldine A Fuller-Bicer, Gyula Varadi, Sheryl E Koch, et al.
Journal of Medicinal Chemistry|April 9, 2015
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep)William H Parsons, Raul R Calvo, Wing Cheung, et al.
Journal of Medicinal Chemistry|March 18, 2005
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonistDevin M Swanson, Adrienne E Dubin, Chandra Shah, et al.
Neuro-Oncology|August 2, 2024
A low level of tumor necrosis factor α in tumor microenvironment maintains the self-renewal of glioma stem cells by Vasorin-mediated glycolysisYang Zhang, Tianxu Kang, Yuxi Wang, et al.
Nature Communications|June 6, 2026
IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2Po Zhang, Weichi Wu, Tengfei Huang, et al.
Neuro-Oncology|June 7, 2025
Nuclear cholesterol regulates nuclear size and DNA damage responses in cancer stem cellsTingting Duan, Suchet Taori, Shruti Bhargava, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 13, 2023
Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 AcetylationHuan Li, Chao Song, Yang Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2019
Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase InhibitorRyan M Wyatt, Ian Fraser, Natalie Welty, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarizationJinyang Hu, Feng Dong, You He, et al.
American Journal of Physiology. Heart and Circulatory Physiology|May 12, 2009
Targeted disruption of the voltage-dependent calcium channel alpha2/delta-1-subunitGeraldine A Fuller-Bicer, Gyula Varadi, Sheryl E Koch, et al.
Journal of Medicinal Chemistry|April 9, 2015
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep)William H Parsons, Raul R Calvo, Wing Cheung, et al.
Journal of Medicinal Chemistry|March 18, 2005
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonistDevin M Swanson, Adrienne E Dubin, Chandra Shah, et al.
Neuro-Oncology|August 2, 2024
A low level of tumor necrosis factor α in tumor microenvironment maintains the self-renewal of glioma stem cells by Vasorin-mediated glycolysisYang Zhang, Tianxu Kang, Yuxi Wang, et al.
Nature Communications|June 6, 2026
IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2Po Zhang, Weichi Wu, Tengfei Huang, et al.
Neuro-Oncology|June 7, 2025
Nuclear cholesterol regulates nuclear size and DNA damage responses in cancer stem cellsTingting Duan, Suchet Taori, Shruti Bhargava, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 13, 2023
Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 AcetylationHuan Li, Chao Song, Yang Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2019
Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase InhibitorRyan M Wyatt, Ian Fraser, Natalie Welty, et al.
Pageof 22